The question we've heard most this week is a simple one: "So BPC-157 is legal now?"

The answer is more nuanced than the headline. On October 30, the Department of Health and Human Services announced a draft policy saying it does not intend to take enforcement action against certain licensed pharmacies and physicians compounding six peptides under specified conditions: BPC-157, TB-500, MOTS-c, epitalon, semax and KPV. That is a statement about enforcement. It is not FDA approval, and it does not add these peptides to the FDA's 503A bulks list.

That distinction matters. The policy is interim and nonbinding, and HHS says it may revisit it. The evidence for these compounds has not changed just because the enforcement posture has.

For those of you on a protocol that includes any of these: nothing changes in your plan today. We've read the policy and its appendices in full, we're tracking it closely, and if anything about how we source or prescribe needs to change, you'll hear it from us directly.

2:42 with Dr. Gupta on what the new peptide policy does, and what it doesn't.

Presented with an AI-generated avatar and voice of Dr. Gupta, from his reviewed script.

HHS has outlined a conditional non-enforcement policy for six peptides: a meaningful step toward supervised access, but not FDA approval.

September 2023. The FDA placed about nineteen peptides, BPC-157 among them, in "Category 2," its designation for substances with significant safety concerns. Most reputable compounding pharmacies stopped making them. Demand didn't go away. It moved online, to vials sold as "research chemicals."

April 2026. The groups that had originally nominated twelve of those peptides for Category 2 withdrew their nominations, and the FDA removed them from the category. That sounded like a reversal. It wasn't one. As HHS itself now confirms, coming off Category 2 didn't change these peptides' legal status, because they had never been on the FDA's list of approved compounding ingredients in the first place.

July 2026. A newly reconstituted FDA advisory committee voted to recommend adding six of seven peptides to that list. The votes were close (8–6 for BPC-157, TB-500 and KPV; 8–5 for semax; 7–4 for epitalon; 7–5 for MOTS-c), and they went against the FDA's own reviewers, who had recommended against all seven. (We walked through that vote in July.)

Adding an ingredient to the list properly takes formal rulemaking: a proposed rule, public comment, a final rule. Lawyers estimate 12 to 24 months. Rather than wait, HHS issued this policy to cover the gap.

It tells pharmacies and physicians that HHS won't take enforcement action if they compound these six peptides under ten conditions. The important ones:

We'll say it plainly: this is a better situation than the one it replaces.

We expect peptide prescribing to move further into the mainstream. Many existing telehealth companies will likely add peptides to their offerings, making them easier for folks to find and discuss with a prescriber.

We also hope this shift means fewer people buy products sold online as "research use only." These vials can have uncertain sourcing and poor quality control. Contamination, including bacterial endotoxins, is a particular concern, especially for injectable products. A licensed pharmacy and physician oversight offer quality controls and clinical monitoring that an online vial may lack. They do not establish that a given peptide is safe or effective, and the policy will not make every source or prescription appropriate.

It's fragile. HHS issued the policy after FDA staff recommended against listing all seven peptides considered by the advisory committee. A petition has asked the FDA to disregard the committee's vote. What one administration grants by policy, another can take back.

Expect a flood. Companies that lobbied for this policy are ready to sell. Over the next few months you'll see a lot of slick offers for peptides. Easier access doesn't change the evidence, and it doesn't replace a physician who knows your history, your labs and your other medications. The right question isn't "can I get it?" It's "should I, and how will we know if it's working?"

"Allowed" isn't the same as "proven." The FDA reviewed each peptide only for the use it was originally nominated for. Epitalon, for example, was reviewed for insomnia, not for longevity. A favorable vote on a molecule isn't evidence that it works for the reason you might want it.

Our read: the policy holds, and over the next year or two the FDA adds most of these six to its formal list through rulemaking. That would create a more durable compounding pathway for any peptides added to the list. It would still not mean FDA approval of a medication. Along the way, watch for three things: the comment period closing November 13; the first safety reports, which could tighten the rules or end them; and the FDA advisory committee's review of five more peptides, expected in February 2027.

We'll keep reading the documents so you don't have to, and we'll tell you when anything changes for your plan.

Explore the Kinetic Edge Health Library. We've built a public library of plain-language cards on many of the peptides people are asking about right now, including what each one is, what the evidence does and doesn't show, and whether it's FDA-approved. Browse it at kineticedgehealth.com/library, and send it to anyone who's asked you about peptides this week.

The fine print. This newsletter is for education and is not individual medical advice. Compounded medications are prescription products that are not FDA-approved and require physician evaluation and ongoing oversight. Talk with your physician before starting, stopping or changing any treatment.

Short-form dispatches on longevity, metabolic health, and men's performance — from the founder of Kinetic Edge Health.

Kinetic Edge Health is a telehealth medical practice licensed in select states. Content on this website is for informational purposes only and does not constitute medical advice. A consultation with a Kinetic Edge Health physician is required before initiating any protocol. Compounded medications are prescription products that are not FDA-approved and require physician evaluation, a valid prescription, and ongoing clinical oversight. Individual results vary. Not available in all states.

Privacy · Terms · Refunds · Shipping · Telehealth Consent

kineticedgehealth.com · Cleveland, OH

© 2026 Kinetic Edge Health, Inc. · All rights reserved.